EUVIMEDEUVIMED entdecken
Crossref

Birth Outcomes Following Anti-viral Therapy for Treatment of COVID-19 During Pregnancy

Hannah Yang, Yosra Elsayed, Victoria Zablocki, Beth Bailey

Maternal and Child Health Journal · 2025

DOI: 10.1007/s10995-025-04091-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Maternal and Child Health Journal, 2025. Verfasst von Hannah Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Central Michigan University College of Medicine, Mount Pleasant, MI, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Pregnancy Outcome, Pregnancy Complications, Infectious, COVID-19 Drug Treatment. Die Arbeit nennt 13 Literaturangaben. Gefördert von: Central Michigan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The aim of this pilot study was to examine, using observational data, birth outcomes following the use of antiviral therapy in pregnancy. METHODS: This retrospective chart review study involved patients diagnosed with COVID-19 who received care at a single university-affiliated obstetrics practice grouped as having received, or not received, Ritonavir-Boosted Nirmatrelvir (NMV-r). Participant background information and birth outcomes were extracted and analyzed. RESULTS: Of 141 patients, nine were prescribed and took a course of NMV-r. Infants born to patients who were pregnantand took NMV-r had significantly shorter hospital stays (average of 2.5 days less) compared to infants born to patients who did not take NMV-r. In addition, there were multiple non-significant but clinically meaningful group differences: more than 10% of those who did not take NMV-r delivered preterm, while all those who took NMV-r delivered after 37 weeks, and infants born to those who did not take NMV-r were three times more likely to be admitted to the NICU compared to infants born to those who took a course of NMV-r. CONCLUSION: Patients who are pregnant andtake NMV-r as treatment for COVID-19 appear to have better birth outcomes than those who do not, with no identified adverse effects in this small convenience sample. Based on this pilot study, NMV-r may improve clinical outcomes for obstetrics patients who contract COVID-19 during pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsPregnancy OutcomePregnancy Complications, InfectiousCOVID-19 Drug TreatmentRitonavirHumansFemalePregnancyRetrospective StudiesPilot ProjectsAdultInfant, NewbornCOVID-19SARS-CoV-2

Stichwörter der Autor:innen

Antiviral agentBirth outcomesCOVID-19Ritonavir-boosted Nirmatrelvir (Paxlovid)

Substanzen

Antiviral AgentsRitonavir

Autor:innen und Institutionen

  • Central Michigan University College of Medicine, Mount Pleasant, MI, USA.
  • Central Michigan University College of Medicine, Mount Pleasant, MI, USA. baile3b@cmich.edu.

Förderung

  • Central Michigan University

Zitieren

APA

Yang, H., Elsayed, Y., Zablocki, V., & Bailey, B. (2025). Birth Outcomes Following Anti-viral Therapy for Treatment of COVID-19 During Pregnancy. Maternal and Child Health Journal. https://doi.org/10.1007/s10995-025-04091-w

Vancouver

Yang H, Elsayed Y, Zablocki V, Bailey B. Birth Outcomes Following Anti-viral Therapy for Treatment of COVID-19 During Pregnancy. Maternal and Child Health Journal. 2025. doi:10.1007/s10995-025-04091-w

BibTeX
@article{Yang2025,
  author = {Yang, Hannah and Elsayed, Yosra and Zablocki, Victoria and Bailey, Beth},
  title = {Birth Outcomes Following Anti-viral Therapy for Treatment of COVID-19 During Pregnancy},
  journal = {Maternal and Child Health Journal},
  year = {2025},
  doi = {10.1007/s10995-025-04091-w}
}
Kostenlos starten →